Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1986 Mar;45(3):177–182. doi: 10.1136/ard.45.3.177

Association of different HLA antigens with various toxic effects of gold salts in rheumatoid arthritis.

M Hakala, A H van Assendelft, J Ilonen, S Jalava, A Tiilikainen
PMCID: PMC1001849  PMID: 3456743

Abstract

An association of gold induced proteinuria with HLA-D(R)3 has been reported. To investigate other possible relationships between gold toxicity and HLA antigens we studied 85 patients with rheumatoid arthritis (RA) divided into four subgroups: patients with gold induced interstitial pneumonitis, mucocutaneous lesions, proteinuria, and patients without gold toxicity. The HLA frequencies in patient groups and 283 healthy controls were compared in different pairwise combinations. Gold induced pneumonitis was associated with HLA-B40 and Dw1. An association between gold induced proteinuria and HLA-Dw3 was also seen. The increased prevalence of Dw4 in RA was observed only in the control patient group without gold induced side effects. The frequencies of HLA-B7 and Dw2 were decreased in all patient groups compared with the control population. These results further support the view of the heterogeneity of RA as manifested by the unique HLA associations with resistance and susceptibility to gold induced side effects characterising different subgroups.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bardin T., Dryll A., Debeyre N., Ryckewaert A., Legrand L., Marcelli A., Dausset J. HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis. Ann Rheum Dis. 1982 Dec;41(6):599–601. doi: 10.1136/ard.41.6.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barger B. O., Acton R. T., Koopman W. J., Alarcón G. S. DR antigens and gold toxicity in white rheumatoid arthritis patients. Arthritis Rheum. 1984 Jun;27(6):601–605. doi: 10.1002/art.1780270601. [DOI] [PubMed] [Google Scholar]
  3. Duquesnoy R. J., Marrari M., Hackbarth S., Zeevi A. Serological and cellular definition of a new HLA-DR associated determinant, MC1, and its association with rheumatoid arthritis. Hum Immunol. 1984 Jul;10(3):165–176. doi: 10.1016/0198-8859(84)90037-5. [DOI] [PubMed] [Google Scholar]
  4. Franzén P., Pettersson T. Alveolitis during chrysotherapy for rheumatoid arthritis. Acta Med Scand. 1983;214(3):249–251. doi: 10.1111/j.0954-6820.1983.tb08603.x. [DOI] [PubMed] [Google Scholar]
  5. Gran J. T., Husby G., Thorsby E. HLA DR antigens and gold toxicity. Ann Rheum Dis. 1983 Feb;42(1):63–66. doi: 10.1136/ard.42.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ilonen J., Lagerstedt A., Koskimies S., Reunanen M. HLA-Dw1 and BfF as protective markers in multiple sclerosis. J Neuroimmunol. 1983 Dec;5(3):283–288. doi: 10.1016/0165-5728(83)90048-6. [DOI] [PubMed] [Google Scholar]
  7. Isomäki H., Nissilä M., Koota K., Martio J., Tiilikainen A. Letter: HL-A 27 and rheumatoid arthritis. Lancet. 1974 Nov 16;2(7890):1212–1213. doi: 10.1016/s0140-6736(74)90858-7. [DOI] [PubMed] [Google Scholar]
  8. Jalava S., Luukkainen R., Hämeenkorpi R., Helve T., Isomäki H. Some characteristics of RA patients with and without side effects due to gold treatment. Scand J Rheumatol. 1977;6(4):206–208. doi: 10.3109/03009747709095450. [DOI] [PubMed] [Google Scholar]
  9. Javaheri S., Lederer D. H., Pella J. A., Mark G. J., Levine B. W. Idiopathic pulmonary fibrosis in monozygotic twins. The importance of genetic predisposition. Chest. 1980 Oct;78(4):591–594. doi: 10.1378/chest.78.4.591. [DOI] [PubMed] [Google Scholar]
  10. Nickels J., van Assendelft A. H., Tukiainen P. Diffuse pulmonary injury associated with gold treatment. Acta Pathol Microbiol Immunol Scand A. 1983 Jul;91(4):265–267. doi: 10.1111/j.1699-0463.1983.tb02756.x. [DOI] [PubMed] [Google Scholar]
  11. Nüsslein H. G., Jahn H., Lösch G., Guggenmoos-Holzmann I., Leibold W., Kalden J. R. Association of HLA-Bw35 with mucocutaneous lesions in rheumatoid arthritis patients undergoing sodium aurothiomalate therapy. Arthritis Rheum. 1984 Jul;27(7):833–836. doi: 10.1002/art.1780270718. [DOI] [PubMed] [Google Scholar]
  12. Panayi G. S., Wooley P., Batchelor J. R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J. 1978 Nov 11;2(6148):1326–1328. doi: 10.1136/bmj.2.6148.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  14. Schiff B., Mizrachi Y., Orgad S., Yaron M., Gazit E. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis. 1982 Aug;41(4):403–404. doi: 10.1136/ard.41.4.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schmidt K. L., Mueller-Eckhardt C. Agranulocytosis, levamisole, and HLA-B27. Lancet. 1977 Jul 9;2(8028):85–85. doi: 10.1016/s0140-6736(77)90082-4. [DOI] [PubMed] [Google Scholar]
  16. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978 Apr 20;298(16):869–871. doi: 10.1056/NEJM197804202981602. [DOI] [PubMed] [Google Scholar]
  17. Svejgaard A., Jersild C., Nielsen L. S., Bodmer W. F. HL-A antigens and disease. Statistical and genetical considerations. Tissue Antigens. 1974;4(2):95–105. doi: 10.1111/j.1399-0039.1974.tb00230.x. [DOI] [PubMed] [Google Scholar]
  18. Tala E., Jalava S., Nurmela T., Vuori K. Pulmonary infiltrates associated with gold therapy. Report of a case. Scand J Rheumatol. 1979;8(2):97–100. doi: 10.3109/03009747909105344. [DOI] [PubMed] [Google Scholar]
  19. Terho E. O., Torkko M., Valta R. Pulmonary damage associated with gold therapy. A report of two cases. Scand J Respir Dis. 1979 Dec;60(6):345–349. [PubMed] [Google Scholar]
  20. Thomsen M., Morling N., Snorrason E., Svejgaard A., Sørensen S. F. HLA--Dw4 and rheumatoid arthritis. Tissue Antigens. 1979 Jan;13(1):56–60. doi: 10.1111/j.1399-0039.1979.tb01137.x. [DOI] [PubMed] [Google Scholar]
  21. Tiilikainen A., Lassus A., Karvonen J., Vartiainen P., Julin M. Psoriasis and HLA-Cw6. Br J Dermatol. 1980 Feb;102(2):179–184. doi: 10.1111/j.1365-2133.1980.tb05690.x. [DOI] [PubMed] [Google Scholar]
  22. Turunen O., Lundqvist C., Julin M., Holmlund G., Tiilikainen A., de la Chapelle A. Stimulatory and cytotoxic activity on human adult and fetal lymphocytes by heterologous antihuman fetal lymphocyte sera. Transplantation. 1979 May;27(5):304–308. doi: 10.1097/00007890-197905000-00003. [DOI] [PubMed] [Google Scholar]
  23. Veys E. M., Mielants H., Rosenthal M. Agranulocytosis, levamisole, and HLA-B27. Lancet. 1977 Oct 8;2(8041):764–764. doi: 10.1016/s0140-6736(77)90270-7. [DOI] [PubMed] [Google Scholar]
  24. Woodrow J. C., Nichol F. E., Zaphiropoulos G. DR antigens and rheumatoid arthritis: a study of two populations. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1287–1288. doi: 10.1136/bmj.283.6302.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  26. Young A., Jaraquemada D., Awad J., Festenstein H., Corbett M., Hay F. C., Roitt I. M. Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities. Arthritis Rheum. 1984 Jan;27(1):20–25. doi: 10.1002/art.1780270104. [DOI] [PubMed] [Google Scholar]
  27. de Jongh B. M., van Romunde L. K., Valkenburg H. A., de Lange G. G., van Rood J. J. Epidemiological study of HLA and GM in rheumatoid arthritis and related symptoms in an open Dutch population. Ann Rheum Dis. 1984 Aug;43(4):613–619. doi: 10.1136/ard.43.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES